A rare variation of the APOE gene may help explain why some people are better protected against the brain changes associated with Alzheimer's disease. Discoveries like this matter because they point researchers toward new prevention strategies. But for the public, an essential nuance remains: protective genetics is not the same as guaranteed protection.
The APOE gene: three alleles, three different stories
The APOE gene codes for apolipoprotein E, a protein involved in lipid transport in the blood and brain. It exists in three main forms: ε2, ε3, and ε4. Each person inherits two copies, one from each parent.
- APOE ε3 is by far the most common (~75–80% of alleles in most populations). It is considered "neutral" with respect to Alzheimer's risk.
- APOE ε4 is the most-studied risk allele. A single ε4 copy increases the risk of late-onset Alzheimer's about 3-fold; two copies, about 8 to 12-fold.
- APOE ε2 is the rarest of the three (~5–10% of alleles). Its main feature is the opposite: it is associated with a reduced risk of Alzheimer's disease.
Why ε2 appears protective
Research over the past three decades, beginning with Corder and colleagues (1994), has consistently shown that ε2 carriers are under-represented among Alzheimer's patients and over-represented among people who reach old age cognitively intact. The exceptional case is the ε2/ε2 homozygotes, people who carry two copies, who represent only about 0.5 to 1% of the population.
A 2020 study from Reiman and colleagues, published in Nature Communications and analysing more than 5,000 brain autopsies, found that ε2/ε2 individuals showed an exceptionally low likelihood of Alzheimer's pathology, even at advanced ages.
The proposed biological mechanisms
- Reduced amyloid deposition: the ε2 isoform appears to bind beta-amyloid less efficiently and to clear it from the brain better than ε4.
- Healthier lipid metabolism: ε2 is associated with lower LDL cholesterol, and cardiovascular health is closely linked to brain health.
- Reduced neuroinflammation: the ε2 isoform appears to dampen the chronic neuroinflammation that contributes to neuronal damage.
The Christchurch case: an exceptional discovery
In 2019, the case of a Colombian woman who carried a familial Alzheimer's-causing mutation (PSEN1) but did not develop dementia until her 70s captured the medical world's attention. The reason: she had two copies of an extremely rare variant called APOE3 Christchurch. This single case has opened a new line of research aimed at developing therapies that mimic this protection.
Important nuance: protective ≠ guaranteed
Carrying ε2 does not eliminate the risk of Alzheimer's. Many other factors influence final risk:
- Lifestyle (Mediterranean diet, regular physical activity, sleep quality)
- Cardiovascular and metabolic health (blood pressure, blood glucose)
- Cognitive activity and social connections
- Other genetic variants that modulate risk
The opposite is also true: people carrying ε4 are not destined to develop Alzheimer's. Genetics establishes a tendency, daily life shapes the actual outcome.
The connection with your FuelYourDNA profile
APOE is one of the most important genes for understanding the link between nutrition and brain health. If you carry the ε4 allele, our recommendations on saturated fats, omega-3, and antioxidants become particularly relevant. If you carry ε2, you have a metabolic advantage, but maintaining it requires nourishing it through your diet.
The methylation cycle (MTHFR, MTR, MTRR) and homocysteine metabolism also play crucial roles in brain health. Elevated homocysteine is an independent risk factor for cognitive decline, and your variants in these genes determine your specific needs in B vitamins (folate, B12, B6).
"Genetics is the score; lifestyle is the orchestra. Even with a favourable score, the music depends on how it is played."
Scientific References
- Reiman EM, et al. (2020). Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes. Nature Communications, 11(1), 667. PubMed 32015339
- Arboleda-Velasquez JF, et al. (2019). Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 25(11), 1680–1683. PubMed 31686034
- Corder EH, et al. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genetics, 7(2), 180–184. PubMed 7920638
- Liu CC, et al. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology, 9(2), 106–118. PubMed 23296339
- Suri S, et al. (2013). The forgotten APOE allele: a review of the evidence and suggested mechanisms for the protective effect of APOE ε2. Neuroscience & Biobehavioral Reviews, 37(10 Pt 2), 2878–2886. PubMed 24080207